MD&AFiled on Sedar. I suggest any serious investor read it. I note the following
The Company will also continue to identify potential in- licensing/acquisition opportunities for additional proprietary and innovative therapeutics.
This was as I suggested a few days ago.
No mention of a US stock filing.